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ABSTRACT T lymphocyte activation through the T cell receptor (TCR)/CD3 complex alters the avidity of the cell surface
adhesion receptor CD2 for its ligand CD58. Based on the observations that activation-associated increases in intracellular
[Ca2] ([Ca2]i) strengthen interactions between T cells and antigen-presenting cells, and that the lateral mobility of cell
surface adhesion receptors is an important regulator of cellular adhesion strength, we postulated that [Ca2]i controls CD2
lateral mobility at the T cell surface. Human Jurkat T leukemia cells were stimulated by antibody-mediated cross-linking of the
TCR/CD3 complex. CD2 was labeled with a fluorescently conjugated monoclonal antibody. Quantitative fluorescence
microscopy techniques were used to measure [Ca2]i and CD2 lateral mobility. Cross-linking of the TCR/CD3 complex
caused an immediate increase in [Ca2]i and, 10–20 min later, a decrease in the fractional mobility of CD2 from the control
value of 68  1% to 45  2% (mean  SEM). One to two hours after cell stimulation the fractional mobility spontaneously
returned to the control level. Under these and other treatment conditions, the fraction of cells with significantly elevated
[Ca2]i was highly correlated with the fraction of cells manifesting significantly reduced CD2 mobility. Pretreatment of cells
with a calmodulin inhibitor or a calmodulin-dependent kinase inhibitor prevented Ca2-mediated CD2 immobilization, and
pretreatment of cells with a calcineurin phosphatase inhibitor prevented the spontaneous reversal of CD2 immobilization.
These data suggest that T cell activation through the TCR/CD3 complex controls CD2 lateral mobility by a Ca2/calmodulin-
dependent mechanism, and that this mechanism may involve regulated phosphorylation and dephosphorylation of CD2 or a
closely associated protein.
INTRODUCTION
T lymphocyte activation, proliferation, and differentiation
are induced upon ligation of antigen-specific T cell recep-
tors (TCRs) by antigen/major histocompatibility complex
(MHC) proteins on antigen-presenting cells (APCs). Other
T cell surface molecules also contribute to TCR-mediated
activation by increasing the adhesion strength between T
cells and APCs and by providing costimulatory signals to T
cells (Springer, 1990). The T cell adhesion receptor CD2
binds CD58 (also known as lymphocyte function-associated
antigen 3, LFA-3), CD59 (Deckert et al., 1992; Hahn et al.,
1992), and CD48 (Arulanandam et al., 1993; Kato et al.,
1992) on APCs, whereas T cell CD11a/CD18 (LFA-1)
binds CD54, CD102, and CD50 (also known as intercellular
adhesion molecules (ICAMs) 1, 2, and 3, respectively)
(Springer, 1990). By stimulating intracellular signal trans-
duction pathways, TCR-mediated T cell activation tran-
siently up-regulates the avidity of CD2 for CD58 and the
avidity of CD11a/CD18 for CD54 (Dustin and Springer,
1989; Hahn et al., 1993). Interactions between T cells and
APCs are also dynamic, involving cycles of cell-cell adhe-
sion and detachment (Martz, 1977; Martz et al., 1983;
Poenie et al., 1987). Intracellular signals may regulate such
adhesion and detachment cycles by coupling TCR ligation
to adhesion molecule avidity.
Adhesion strength is determined both by the intrinsic
affinity of binding between receptors and ligands and by the
density of these adhesion molecules at contact sites. Redis-
tributions of adhesion molecules to and from sites of contact
between lymphocyte and target membranes may be impor-
tant steps in cell-cell adhesion and detachment events
(Boniface and Davis, 1995; Dustin et al., 1996; Koyasu et
al., 1990). Adhesion molecules must be capable of lateral
movement in the plane of the plasma membrane for such
molecules to redistribute to contact sites. Experiments in
which Jurkat T leukemia cells were found to adhere more
strongly to laterally mobile CD58 than to immobile CD58
reconstituted in glass-supported planar bilayer membranes
have demonstrated the importance of adhesion molecule
lateral mobility for cellular adhesion strength (Chan et al.,
1991).
T cell stimulation through the TCR/CD3 complex ini-
tiates a series of intracellular events, including activation of
protein tyrosine kinases and of phospholipase C (see Weiss
and Littman, 1994). Phospholipase C mediates hydrolysis of
phosphatidylinositol-4,5-bisphosphate to generate inositol-
1,4,5-trisphosphate and 1,2-diacylglycerol, which induce,
respectively, an increase in intracellular [Ca2] ([Ca2]i)
and activation of protein kinase C (PKC). Although both
tyrosine kinase and PKC activation are involved in the
TCR-mediated enhancement of CD2 avidity for CD58
(Hahn et al., 1993), several lines of evidence suggest that
intracellular Ca2 plays an important role in regulating T
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cell interactions with APCs. The kinetics and magnitude of
Ca2 signals appear to correlate with those of T cell acti-
vation (Wulfing et al., 1997). An increase in intracellular
[Ca2] stabilizes the interaction of T cells with APCs and
reduces the ability of T cells to migrate (Donnadieu et al.,
1994; Negulescu et al., 1996). We hypothesize that one
mechanism by which intracellular Ca2 controls adhesion
strength involves regulation of CD2 lateral mobility and cell
surface distribution. By specifically immobilizing CD2
molecules that accumulate at cell-cell contact sites, for
example, intracellular Ca2 could increase the probability
of formation of adhesive molecular contacts and decrease
the chemical activity of the stabilized CD2-CD58 adhesion
complexes (Zhu et al., manuscript in preparation) and
thereby increase cellular adhesion strength, stabilize T cell-
APC interactions, and reduce T cell migration. We have
previously demonstrated that T cell stimulation by pairs of
anti-CD2 monoclonal antibodies (mAbs) causes immobili-
zation of cell surface CD2, and that this CD2 immobiliza-
tion is mediated in part by increases in [Ca2]i (Liu et al.,
1995). In this report, we extend this hypothesis to the more
physiological case by quantifying the degree to which TCR-
mediated changes in [Ca2]i regulate CD2 lateral mobility.
We also investigate the intracellular events that mediate
changes in CD2 lateral mobility upon cell stimulation
through the TCR/CD3 complex. These studies may provide
the molecular link by which T cell activation is coupled to
changes in CD2 mobility and distribution, and thereby to
alterations in CD2 avidity.
MATERIALS AND METHODS
Cell lines and antibodies
Jurkat T leukemia cells were maintained in RPMI 1640 (Sigma Chemical
Co., St. Louis, MO) supplemented with 10% heat-inactivated fetal bovine
serum (Hyclone Laboratories, Logan, UT), 100 units/ml penicillin-100
g/ml streptomycin (Sigma), 3 mM glutamine (Gibco BRL, Gaithersburg,
MD), and 50 M 2-mercaptoethanol (Sigma) at 37°C in a 5% CO2
atmosphere. The anti-CD2 mAb TS2/18 (subclass IgG1; Sanchez-Madrid
et al., 1982) was conjugated to fluorescein isothiocyanate (FITC), as
described (Golding, 1976; Stolpen et al., 1988). OKT3 (subclass IgG2a) is
an anti-CD3 mAb (Sigma Immunochemicals). Goat anti-mouse IgG2a
(GaM; Caltag Laboratories, San Francisco, CA) was used to cross-link
OKT3. 9–1 is an anti-CD2R mAb (Bernard et al., 1986). Antibodies were
centrifuged at 16,000  g (model 5412; Eppendorf, Hamburg, Germany)
for 1 h immediately before experiments.
Cell preparation
Cells were washed with HEPES-buffered saline (HBS) (140 mM NaCl, 2
mM KCl, 0.5 mM CaCl2, 0.5 mM MgCl2, 20 mM HEPES, 5.6 mM
glucose, pH 7.4). For fluorescence photobleaching recovery (FPR) exper-
iments, cell surface CD2 molecules were labeled with FITC-conjugated
TS2/18 (FITC-TS2/18) by incubating cells (5  106/ml) with FITC-
TS2/18 (50 g/ml) for 30 min at 0°C in the dark. For intracellular Ca2
measurements, cells were incubated with 10 M fluo-3-acetoxymethyl
ester (Molecular Probes, Eugene, OR) for 1 h at room temperature, as
described (Liu et al., 1995).
Cell pretreatment
W-7 (Seikagaku America, Rockville, MA), cyclosporine A (CsA) (Sandoz
Research Institute, Hanover, NJ), and KN-62 (Seikagaku America) were
dissolved in H2O, ethanol, and dimethyl sulfoxide to make 5 mM, 1 mM,
and 10 mM stock solutions, respectively. Other reagents were dissolved in
HBS.
Jurkat cells were incubated in the dark with trifluoperazine (TFP)
(Sigma) for 15 min at 37°C; with 100 MW-7, 50 M KN-62, or CsA for
1 h at 37°C; or with 500 nM okadaic acid (Calbiochem, La Jolla, CA) for
30 min at room temperature. For some experiments, intracellular Ca2 was
depleted by pretreating cells with 10 mM EGTA and 10 M ionomycin
(EGTA  ionomycin) in HBS for 1 h at room temperature. None of these
pretreatments caused a change in cell morphology by phase-contrast mi-
croscopy. By trypan blue exclusion, 90% of cells remained viable after
each pretreatment. All pretreatments were carried out before fluorescent
labeling and mAb stimulation of cells.
Cell stimulation
Cells (5  106/ml) were incubated with TS2/18 or FITC-TS2/18 (50
g/ml) in HBS for 10 min on ice, then incubated with OKT3 (50 g/ml)
 TS2/18 or FITC-TS2/18 in HBS for 20 min on ice, then washed with
HBS. Unless otherwise indicated, GaM (50 g/ml) was added to the cell
suspension immediately before lateral mobility or [Ca2]i measurements.
In some experiments (see Fig. 6), cells were incubated with FITC-TS2/18
for 30 min on ice, then OKT3 was added to the cell suspension immedi-
ately before lateral mobility or [Ca2]i measurements. Samples pretreated
with EGTA  ionomycin or with a pharmacological inhibitor were main-
tained in HBS with EGTA  ionomycin or with the inhibitor throughout
the incubation, mAb stimulation, and data collection steps. Jurkat cells
were alternatively stimulated by using a pair of anti-CD2 mAbs, 9–1 
FITC-TS2/18. Cells were first labeled with FITC-TS2/18, then 9–1 (50
g/ml) was added to the cell suspension immediately before lateral mo-
bility or [Ca2]i measurements.
Fluorescence photobleaching recovery
An ACAS 570 interactive laser cytometer (Meridian Instruments, Okemos,
MI) was used to perform fluorescence photobleaching recovery (FPR)
experiments (Axelrod et al., 1976), as described (Liu et al., 1995). Briefly,
a Gaussian laser beam was focused to a spot on a labeled cell in a
fluorescence microscope. After a brief, intense photobleaching pulse, re-
covery of fluorescence was monitored by periodic pulses of lower inten-
sity. Fluorescence recovery resulted from the lateral diffusion of un-
bleached fluorophores into the bleached area. The Gaussian beam radius
was 1 m, and excitation and emission wavelengths were 488 nm and
510  5 nm, respectively. Photobleaching power at the sample was 0.5
mW, and the bleaching time was 40–50 ms. The fractional mobility (f
value; the fraction of FITC-labeled protein that was free to diffuse in the
plane of the membrane) and the lateral diffusion coefficient (D) of the
mobile fraction were obtained by nonlinear least-squares analysis of fluo-
rescence recovery curves (Golan et al., 1986).
Intracellular calcium ion concentration
The ACAS 570 interactive laser cytometer was used to image individual
fluo-3-loaded cells, using an excitation wavelength of 488 nm and an
emission wavelength of 510 nm. Integrated single-cell fluo-3 fluorescence
intensities were then measured. Fluo-3 spectral response was calibrated
using Mn2, and [Ca2]i was calculated from the integrated single-cell
fluo-3 fluorescence intensity, based on the method described by Kao et al.
(Kao et al., 1989; Liu et al., 1995). Fluo-3-loaded cells were treated with
mAbs (TS2/18 or TS2/18 OKT3) and washed. GaM (50 g/ml) was then
added to the cell suspension. Single-cell images were taken immediately
after fluo-3 loading and after each antibody treatment. Because calcium
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dyes such as fluo-3 are rapidly internalized into pinocytic vesicles and
other intracellular organelles at 37°C, the calcium imaging experiments
were performed at room temperature. To ensure uniformity of cell treat-
ment between CD2 lateral mobility and [Ca2]i experiments, lateral mo-
bility measurements were also made at room temperature.
RESULTS
T cell stimulation through the TCR/CD3 complex
induces a reversible decrease in the fractional
mobility of CD2
Jurkat T cells were stimulated by cross-linking of the TCR/
CD3 complex with the anti-CD3 mAb OKT3 (subclass
IgG2a) and goat anti-mouse IgG2a (GaM). CD2 was fluo-
rescently labeled with FITC-conjugated TS2/18, an anti-
CD2 mAb, and FPR was used to measure CD2 lateral
mobility. Fluorescence imaging of FITC-TS2/18-labeled
resting and stimulated cells showed the characteristic
plasma membrane “rim” stain; 29% of resting cells and 49%
of stimulated cells were also found to have one or two
fluorescent patches (2 m in diameter) in the plasma
membrane.
To test the effect of TCR-mediated T cell stimulation on
CD2 lateral mobility, cells were first incubated with FITC-
TS2/18 and OKT3; then GaM was added to the cell sus-
pension. Control FITC-TS2/18-labeled cells manifested a
CD2 fractional mobility of 68  1% (mean  SEM).
Treatment with either OKT3 or GaM did not significantly
change the fractional mobility. In contrast, cross-linking of
OKT3 by GaM induced time-dependent immobilization of
CD2. The fractional mobility decreased significantly 20 min
after GaM addition and remained at a level of 45  2% for
21–60 min of incubation (Fig. 1, a and b, Table 1). The
fractional mobility then increased spontaneously 1 h after
GaM addition, returning to baseline levels 2 h after GaM
addition and remaining at this level for at least 1.5 addi-
tional hours (Fig. 2 a). T cell stimulation through the TCR/
CD3 complex was therefore associated with a significant,
reversible decrease in CD2 fractional mobility.
An apparent decrease in fractional mobility could result
from immobilization of fluorescently labeled cell surface
receptors or, alternatively, from internalization of labeled
receptors (Thatte et al., 1994) upon T cell stimulation.
Receptor internalization would be expected to shift the
fluorescence distribution from the periphery to the center of
cells. The distribution of FITC-TS2/18 fluorescence inten-
sity along the axis of laser scanning was similar on resting
cells and on cells stimulated with OKT3  GaM (data not
shown), suggesting that CD2 internalization was not re-
sponsible for the decrease in CD2 lateral mobility. Rather,
the decrease in fractional mobility was due to CD2 immo-
bilization at the cell surface.
Intracellular calcium ions mediate the
TCR-induced CD2 immobilization
We have previously shown that T cell activation through
CD2 induces both an increase in [Ca2]i and a marked
decrease in CD2 lateral mobility, and that the increase in
[Ca2]i is responsible in part for the CD2 immobilization
(Liu et al., 1995). Because T cell stimulation through the
TCR/CD3 complex also decreased CD2 fractional mobility,
we hypothesized that intracellular Ca2 could act as a
common regulator of CD2 lateral mobility and attempted to
determine whether the TCR-induced immobilization of
CD2 was caused by an increase in [Ca2]i.
[Ca2]i was measured in single cells before and after T
cell stimulation. Relative fluorescence intensity was used to
characterize changes in [Ca2]i under various experimental
conditions. As previously observed (Yang et al., 1987),
treatment of Jurkat T cells with the single anti-CD2 mAb
TS2/18 did not cause an increase in [Ca2]i. Similarly,
treatment with TS2/18 and GaM did not increase [Ca2]i
(data not shown). Treatment with TS2/18 and OKT3 caused
a small but significant increase in [Ca2]i (Fig. 3); this
increase occurred immediately after stimulation with OKT3
and did not change significantly over 20 min of incubation
(data not shown). Cross-linking of the TCR/CD3 complex
by addition of GaM to OKT3-treated cells caused a more
prominent [Ca2]i elevation. This increase in [Ca
2]i oc-
curred immediately after GaM addition, peaked at 11–20
min of incubation, and declined to baseline levels by 41–50
min of incubation (Fig. 3).
To determine whether intracellular Ca2 was required for
CD2 immobilization, cells were depleted of intracellular
Ca2 by pretreatment with EGTA  ionomycin. This pre-
treatment lowered the [Ca2]i from 115 nM to 18 nM in
resting cells and completely eliminated the increase in
[Ca2]i upon stimulation with OKT3  GaM. The frac-
tional mobility of CD2 in cells depleted of intracellular
Ca2 remained constant (f value, 65–70%) for 60 min after
the addition of GaM to cells treated with TS2/18 and OKT3
(Table 1, Fig. 1 c), suggesting that intracellular Ca2 was
required for TCR-induced CD2 immobilization.
The degree of CD2 immobilization correlates
directly with the increase in intracellular calcium
ion concentration
T cell stimulation, through either the TCR/CD3 complex
(the present study) or CD2 (Liu et al., 1995), caused both an
increase in [Ca2]i and a decrease in CD2 mobility. Because
the magnitude of the changes in CD2 mobility and in
[Ca2]i differed between cells stimulated through the TCR/
CD3 complex and cells stimulated through CD2, we could
test the hypothesis that CD2 immobilization correlates di-
rectly with the increase in [Ca2]i. The single cell distribu-
tions of CD2 mobility and [Ca2]i were measured in cells
stimulated by various combinations of antibodies. We pre-
dicted that if the increase in [Ca2]i caused CD2 immobi-
lization, then for each experimental treatment the fraction of
cells with high [Ca2]i (Ra) would equal the fraction of
cells with low CD2 mobility (Rf). (Optimally, measure-
ments of CD2 mobility and [Ca2]i would have been per-
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FIGURE 1 Time course of CD2 immobilization induced by stimulation of Jurkat T cells through the TCR/CD3 complex, and effects of intracellular Ca2
depletion, CaM inhibition, and CaM kinase inhibition on the immobilization of CD2. Cells were treated with FITC-TS2/18  OKT3 (a, c–f) or
FITC-TS2/18 alone (b). Goat anti-mouse IgG2a (GaM) was added at time 0 to cross-link the TCR/CD3 complex. In some experiments cells were pretreated
with 10 mM EGTA  10 M ionomycin (c), 100 nM trifluoperazine (TFP) (d), 100 M W-7 (e), or 50 M KN-62 (f). Data points represent the mean 
SEM of 19–39 (a–c) or 8–18 (d–f) measurements of CD2 fractional mobility (f, %) from 8 (a), 6 (b), 7 (c), 3 (d), or 2 (e, f) independent experiments in
each time interval. By Student’s two-tailed t-test, the mean f values in b–f are significantly different from those in a at each of the corresponding time
intervals, with p  0.05 (*), p  0.01 (**), or p  0.001 (***).
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formed in the same cells at the same time for each experi-
mental treatment. We could not identify a pair of fluorescent
labels that would allow such simultaneous measurements,
however. For example, although both FITC-TS2/18 and the
calcium dye fura red could be excited by 488-nm light, the
spectral overlap between the weak FITC emission and the
strong fura red emission prevented signal separation ade-
quate for this study.)
Objective cutoff values were determined for the [Ca2]i
and CD2 fractional mobility that corresponded to cell stim-
ulation. The distribution of [Ca2]i values in cells treated
with TS2/18 and OKT3 followed by GaM (stimulated cells)
was compared to that in cells treated with TS2/18 and GaM
(control cells). Compared to control cells, stimulated cells
showed a lower fraction of cells with [Ca2]i 200 nM and
a higher fraction of cells with [Ca2]i  400 nM (Fig. 4 a).
The critical value of [Ca2]i was taken to be that at which
the distribution profiles of [Ca2]i for stimulated and con-
trol cells intersected. Finer analysis showed that these two
profiles intersected at 280 nM (Fig. 4 b). Similar experi-
ments were performed to compare the distribution profiles
of [Ca2]i values in cells treated with the anti-CD2 mAb
pair TS2/18  9–1 (stimulated cells) and control cells.
These two distribution profiles again intersected at 280 nM
(Fig. 4, c and d). An [Ca2]i of 280 nM was therefore used
as the cutoff value that characterized cell stimulation, and
Ra was defined as the fraction of cells with [Ca
2]i  280
nM.
Next the distribution of CD2 f values in cells treated with
TS2/18 and OKT3 followed by GaM (stimulated cells) was
compared to that in cells treated with TS2/18 alone or
TS2/18 and GaM (control cells). The distribution profiles
for stimulated cells (Fig. 5 c) and control cells (Fig. 5, a and
b) intersected at an f value of 50%. Because depletion of
intracellular Ca2 prevented the CD2 immobilization in-
duced by cross-linking of the TCR/CD3 complex (Figs. 1 b
and 5 e), we also compared the distribution of f values in
stimulated cells (Fig. 5 c) with that in cells pretreated with
EGTA  ionomycin and then treated with OKT3 followed
by GaM (Fig. 5 e). The latter two profiles also intersected at
an f value of 50%. Therefore, a fractional mobility of 50%
was used as the cutoff value that characterized TCR-medi-
ated cell stimulation, and Rf was defined as the fraction of
either control cells or cells stimulated through the TCR with
a CD2 f value  50%.
Stimulation of T cells by pairs of anti-CD2 mAbs de-
creases the fractional mobility of CD2 from 70% to 10%.
This effect is mediated in part by mobilization of intracel-
lular Ca2, because intracellular Ca2 depletion causes the
f value of CD2 to decrease to 35% rather than 10% upon
stimulation through CD2 (Liu et al., 1995). To determine a
cutoff value for the CD2 fractional mobility that corre-
sponded to the Ca2-sensitive portion of the CD2 immobi-
lization induced by stimulation through CD2, we compared
the distributions of f values in cells treated with TS2/18 
9–1 to those in cells pretreated with EGTA  ionomycin
and then treated with TS2/18  9–1 (Fig. 5, d and f,
respectively). The two distribution profiles intersected at an
f value of 15%. This fractional mobility was therefore used
as the cutoff value that characterized the Ca2-sensitive
portion of the CD2 immobilization induced by stimulation
through CD2, and Rf was defined as the fraction of cells
stimulated by pairs of anti-CD2 mAbs with a CD2 f
value  15%.
The objective criteria defined above were used to calcu-
late Ra and Rf values for the various control and stimulated
cell populations. Control cells included unlabeled cells and
cells treated with TS2/18 alone or with TS2/18 and GaM.
Stimulated cells included cells treated with TS2/18 and
OKT3, with TS2/18 and OKT3 followed by GaM, or with
TS2/18 and 9–1. Both Ra and Rf values increased in the
following order: control cells  cells treated with OKT3 
cells stimulated by OKT3 followed by GaM  cells stim-
ulated by TS2/18  9–1. For both control and stimulated
cells, Ra values increased in proportion to the correspond-
ing Rf values (Fig. 6), suggesting a strong correlation be-
tween the fraction of cells with elevated [Ca2]i and the
fraction of cells with decreased CD2 mobility. The linear
least-squares fit regression line describing the relationship
between Ra and Rf had a slope of 0.92, a y-intercept of
	0.04, and a correlation coefficient of 0.95.
TABLE 1 Effect of intracellular Ca2 depletion on immobilization of CD2 induced by stimulation of Jurkat T cells through the
TCR/CD3 complex
Pretreatment mAb treatment D ( 1010 cm2 s	1) f (%) N
None TS2/18* 7.5  0.3 68  1 (1, 5, 6, 7, 8) 338
None TS2/18  OKT3* 7.5  0.8 63  3 (2, 5) 34
None TS2/18 3 GaM* 7.0  0.4 65  2 (3, 6) 161
None TS2/18  OKT3 3 GaM# 8.9  0.8 45  2 (1, 2, 3, 4) 72
EGTA  ionomycin TS2/18* 8.6  2.0 65  4 (7, 9) 9
EGTA  ionomycin TS2/18  OKT3* 7.8  0.6 68  3 (9, 10) 54
EGTA  ionomycin TS2/18  OKT3 3 GaM# 7.0  0.9 66  3 (4, 8, 10) 52
After pretreatment, cells were incubated with TS2/18 or TS2/18  OKT3 and then with GaM. FPR was used to measure CD2 lateral mobility 0–60 min
(*) or 21–60 min (#) after the addition of GaM. The time course of CD2 immobilization induced upon addition of GaM is shown in Fig. 1. D, diffusion
coefficient; f, fractional mobility; N, number of measurements. D and f values represent the mean  SEM. 1, 2, 3, 4, p  0.001, Student’s two-tailed t-test.
5, 6, 7, 8, 9, 10, p  0.05, Student’s two-tailed t-test.
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Inhibition of calmodulin or CaM kinase prevents
the CD2 immobilization induced by cross-linking
of the TCR/CD3 complex
The increase in [Ca2]i induced by OKT3  GaM occurred
immediately after GaM addition and peaked at 11–20 min
of incubation (Fig. 3). In contrast, for 10 min after GaM
addition, CD2 mobility remained at control levels, then
began to decrease between 11 and 20 min of incubation and
reached a minimum value (f 
 45%) at 21–30 min after
GaM addition (Fig. 1 a). The 10-min delay between the
significantly different from that at 0.5–1 h after GaM addition (p 0.001).
(b, c) Cells were pretreated with 100 nM cyclosporine A (b) or 500 nM
okadaic acid (c). Data points represent the mean  SEM of 26–43
measurements of CD2 fractional mobility from three experiments (b) and
13–16 measurements of CD2 f value from one experiment (c) in each time
interval. By Student’s two-tailed t-test, the mean f values of cells pretreated
with cyclosporine (b) are significantly different from those of control cells
(a) in the 1.5–2-h time interval (p  0.02) and in all time intervals from 2
to 3.5 h (p  0.001). For comparison the mean fractional mobility of CD2
in cells treated with FITC-TS2/18 alone is shown (dashed line, a).
FIGURE 2 Reversal of CD2 immobilization induced by stimulation of
Jurkat T cells through the TCR/CD3 complex, and effects of phosphatase
inhibition on the reversal of CD2 immobilization. Cells were treated with
FITC-TS2/18  OKT3, then GaM was added at time 0 to cross-link the
TCR/CD3 complex. (a) Data points represent the mean  SEM of 40–150
measurements of CD2 fractional mobility (f, %), including all data pre-
sented in Fig. 1 a and data from three additional experiments in which
measurements were performed for 3.5 h after GaM addition. By Student’s
two-tailed t-test, the mean f value at 1.5–2.0 h after GaM addition is
FIGURE 3 Time course of [Ca2]i changes induced by stimulation of
Jurkat T cells through the TCR/CD3 complex. Cells were loaded with
fluo-3, incubated with mAb-free control medium or with TS2/18 OKT3,
and washed. GaM was then added to the cells at time 0. The fluorescence
intensity of control and TCR-stimulated cells was normalized by the
fluorescence intensity measured in the presence of Mn2, as described in
Materials and Methods, to obtain the relative fluorescence intensity. Data
points represent the mean  SEM of 74–101 measurements from five
independent experiments under each treatment condition. By Student’s
two-tailed t-test, GaM alone did not induce a significant increase in [Ca2]i
(p  0.05), but OKT3 and OKT3  GaM did induce significant increases
in [Ca2]i compared to the [Ca
2]i in control cells (*, p  0.05; **, p 
0.01; ***, p  0.001). The relative fluorescence intensity of cells 11–20
min after GaM addition was significantly different from that of cells treated
with OKT3 alone (p 0.01) and from that of cells at 51–60 min after GaM
addition (p  .01). The fluorescence intensity of control cells did not vary
over the time course of the experiments (not shown).
1684 Biophysical Journal Volume 76 March 1999
increase in [Ca2]i and the decrease in CD2 mobility sug-
gested that modulation of CD2 mobility by intracellular
Ca2 was mediated by intermediate molecular events. To
determine whether intracellular Ca2 regulated CD2 lateral
mobility by activation of the Ca2/CaM pathway, Jurkat
cells were pretreated with a CaM inhibitor, either trifluoper-
azine (TFP) or W-7, and then CD2 lateral mobility was
measured before and after cell stimulation by OKT3 
GaM or by a pair of anti-CD2 mAbs. Pretreatment with TFP
prevented the CD2 immobilization induced by cross-linking
of the TCR/CD3 complex, in a dose-dependent manner. The
minimum CD2 fractional mobility after stimulation with
OKT3  GaM increased with increasing TFP concentra-
tion, reaching the control level (i.e., the level in the absence
of cell stimulation) at concentrations of TFP  100 nM
(Figs. 1 d, 7). Similarly, pretreatment with 100 M W-7
completely prevented the CD2 immobilization induced by
cross-linking of the TCR/CD3 complex (Fig. 1 e). These
data suggested that TFP and W-7 interrupted a stimulation-
induced signaling pathway leading to CD2 immobilization.
Neither TFP nor W-7 inhibited the increase in [Ca2]i
induced by cross-linking of the TCR/CD3 complex (data
not shown). Thus the effects of TFP and W-7 on CD2
immobilization appeared to result from specific inhibition
of CaM activity.
We next determined whether CaM activity was required
for the Ca2-sensitive portion of the CD2 immobilization
induced by a pair of anti-CD2 mAbs. In cells pretreated with
either TFP or W-7, the CD2 fractional mobility decreased
from 65–70% to 40–50% after stimulation by TS2/18 
9–1, whereas in control cells such stimulation resulted in
complete immobilization of CD2 (f  10%) (Table 2). The
CaM-dependent (Table 2) and Ca2-dependent (Fig. 5, d
and f) portions of the CD2 immobilization induced by
TS2/18  9–1 were in quantitative agreement with one
another, providing further support for the hypothesis that
intracellular Ca2 regulated CD2 lateral mobility through
activation of CaM.
Ca2/CaM-dependent protein kinase II (CaM kinase) is
activated by calmodulin. Based on the observation of a
FIGURE 4 Histograms of intracellular [Ca2] in control and stimulated Jurkat T cells, normalized by the total number of cells. Intracellular [Ca2] was
measured in control cells (dark stripes; c, d), cells treated with TS2/18  GaM (black; a, b), cells treated with TS2/18  OKT3 followed by GaM (light
stripes; a, b), and cells treated with TS2/18  9–1 (white; c, d), from 0 to 60 min after the addition of GaM or 9–1. For each experimental condition, the
fractions of cells with [Ca2]i from 0 to 3000 nM were calculated using data pooled from at least three independent experiments. The total numbers of
measurements for each condition were 347 (dark stripes); 279 (black); 547 (light stripes); and 449 (white). b and d represent expanded portions of the data
shown in a and c, respectively. The cutoff [Ca2]i value for cell stimulation was determined to be 280 nM for both TS2/18  OKT33 GaM and TS2/18
 9–1-treated samples (see Results).
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significant delay between the return of [Ca2]i and that of
CD2 fractional mobility toward baseline values after T cell
stimulation by OKT3  GaM (Figs. 1 a, 3), we hypothe-
sized that CaM kinase activation was involved in the induc-
tion and maintenance of CD2 immobilization. Cells were
pretreated with the selective CaM kinase inhibitor KN-62
(Ishikawa et al., 1990; Tokumitsu et al., 1990) and then
stimulated by cross-linking of the TCR/CD3 complex or by
a pair of anti-CD2 mAbs. Pretreatment with KN-62 com-
pletely prevented the CD2 immobilization induced by
OKT3  GaM (Fig. 1 f) and partially prevented the CD2
immobilization induced by TS2/18  9–1 (Table 2). The
effects of this CaM kinase inhibitor were in quantitative
agreement with the Ca2-dependent and CaM-dependent
portions of the CD2 immobilization induced by OKT3 
GaM or by TS2/18  9–1, suggesting that intracellular
Ca2 and CaM regulated CD2 lateral mobility by activating
CaM kinase.
Inhibition of calcineurin phosphatase prevents
the reversal of CD2 immobilization induced by
cross-linking of the TCR/CD3 complex
Calcineurin is a Ca2/CaM-dependent protein serine/threo-
nine phosphatase that dephosphorylates many substrates of
the Ca2/CaM-dependent kinases (Klee, 1991; Klee et al.,
1988; Premack and Gardner, 1992). We hypothesized that
calcineurin phosphatase activity was responsible for the
reversal of CD2 fractional mobility from 45% to 70%
FIGURE 5 Histograms of CD2
fractional mobility in resting cells (a
and b), stimulated cells (c and d), and
cells pretreated with EGTA  iono-
mycin before stimulation (e and f),
normalized by the total number of
measurements. Cells were incubated
with FITC-TS2/18 (a), FITC-TS2/18
 GaM (b), FITC-TS2/18  OKT3
and then GaM (c and e), and FITC-
TS2/18  9–1 (d and f). Fractional
mobility measurements were taken
0–60 min after the addition of GaM
or 9–1. The total numbers of mea-
surements were 338 (a), 161 (b), 145
(c), 429 (d), 154 (e), and 450 (f). Data
sets shown in d and f were taken from
our previous report (table 1 and figure
2 of Liu et al., 1995). Vertical lines
represent the cutoff f values for cell
stimulation, which were determined
to be 50% for TS2/18  OKT3 3
GaM-treated samples and 15% for
TS2/18  9–1-treated samples (see
Results).
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1–2 h after stimulation of T cells by OKT3  GaM. To test
this hypothesis, Jurkat cells were pretreated with the cal-
cineurin phosphatase inhibitor cyclosporine A (CsA), and
CD2 lateral mobility was measured before and after cell
stimulation by OKT3  GaM. Pretreatment with CsA did
not affect the immobilization of CD2 induced by OKT3 
GaM. In a dose-dependent manner, however, CsA did pre-
vent the recovery of CD2 fractional mobility for up to 3.5 h
after OKT3  GaM treatment. The CD2 fractional mobility
1.5–3.5 h after stimulation with OKT3  GaM decreased
with increasing CsA concentration, reaching a minimum
value at concentrations of CsA  100 nM (Figs. 2 b, 8).
Calcineurin can activate protein phosphatase 1 (PP1) and
thereby trigger a protein phosphatase cascade (Cohen, 1989;
Ingerbritsen and Cohen, 1983) that leads to dephosphoryla-
tion and activation of multiple proteins, including CaM
kinase (Klee, 1991). To determine whether the Ca2/CaM-
independent phosphatases were involved in regulation of
CD2 lateral mobility, Jurkat cells were pretreated with the
PP1/PP2A inhibitor okadaic acid, and CD2 lateral mobility
was measured before and after cell stimulation by OKT3 
GaM. Pretreatment with 500 nM okadaic acid did not
change the kinetics of either the decrease or the spontaneous
reversal in CD2 fractional mobility induced by cross-linking
of the TCR/CD3 complex (Fig. 2 c), suggesting that neither
PP1 nor PP2A was involved in initiating CaM kinase-
mediated CD2 immobilization or in reversing the effects of
CaM kinase. Taken together, these data suggested that spe-
cific activation of calcineurin phosphatase by Ca2/CaM
was responsible for the reversal of CD2 immobilization
induced by cross-linking of the TCR/CD3 complex.
DISCUSSION
In this report we show that T cell stimulation by cross-
linking of the TCR/CD3 complex reduces CD2 fractional
mobility from 70% to 45%. This result is consistent
with our previous observation that T cell stimulation by
pairs of anti-CD2 mAbs causes CD2 immobilization (Liu et
FIGURE 6 Linear correlation between fractional [Ca2]i elevation (Ra)
and fractional CD2 lateral immobilization (Rf). Ra represents the fraction
of cells with [Ca2]i greater than 280 nM for each experimental treatment.
Rf represents the fraction of cells with a CD2 f value less than 50%
(control, TO, TOG) or less than 15% (9T). Ra and Rf values (mean 
SEM) were calculated using data pooled from at least three independent
experiments. Rf values were determined for cells treated with FITC-TS2/18
and FITC-TS2/18  GaM (control), FITC-TS2/18  OKT3 (TO), FITC-
TS2/18 OKT3 followed by GaM (TOG), and FITC-TS2/18 9–1 (9T).
These Rf values were significantly different from each other with p  0.05
by Student’s two-tailed t-test; the total numbers of cells per sample were
338 (cont), 149 (TO), 145 (TOG), and 429 (9T). Ra values were calculated
for cells without antibody treatment, cells treated with TS2/18, and cells
treated with TS2/18  GaM (control), and for cells treated with TO, TOG,
and 9T. These Ra values were significantly different from each other with
p  0.01 by Student’s two-tailed t-test; the total numbers of cells per
sample were 278 (control), 377 (TO), 548 (TOG), and 447 (9T). Data were
fitted by linear least-squares regression. The slope of the regression line
was 0.92, the y-intercept was 0.04, and the correlation coefficient R2 was
0.95.
FIGURE 7 Concentration dependence of inhibition of CD2 immobiliza-
tion by trifluoperazine. Jurkat cells were pretreated with various concen-
trations of TFP and then stimulated by cross-linking the TCR/CD3 com-
plex with OKT3  GaM. CD2 fractional mobility was measured 31–60
min after the addition of GaM. Data points represent the mean  SEM of
54–97 measurements of CD2 fractional mobility (f) from at least two
experiments at each TFP concentration.
TABLE 2 Effects of CaM and CaM kinase inhibitors on the
immobilization of CD2 induced by stimulation of Jurkat T cells
through CD2
Pretreatment
mAb treatment
TS2/18 TS2/18  9-1
f (%) N f (%) N
None* 68  1 338 10 (1, 2, 3) 149
TFP 66  3 41 50  2(1) 100
W-7 65  4 14 40  2(2) 62
KN-62 73  3 23 42  2(3) 107
After pretreatment, cells were incubated with TS2/18 and then with 9-1.
FPR measurements of CD2 lateral mobility were made for 60 min after the
addition of 9-1. The time course of CD2 immobilization induced upon the
addition of 9-1 is shown in figure 2 of Liu et al. (1995). f, fractional
mobility; N, number of measurements. f values represent the mean SEM.
*Control data are reproduced from Table 1 of this study and from table 2
of Liu et al. (1995). 1, 2, 3, p  0.001, Student’s two-tailed t-test.
Liu and Golan Intracellular Ca2 Regulates CD2 Diffusion 1687
al., 1995). Similar correlations between cell activation and
surface receptor immobilization have also been found in
neutrophils stimulated with fMLP (Johansson et al., 1993)
and in the human T cell line HPB-ALL stimulated with
bivalent anti-CD3 mAb (Hashemi et al., 1992).
Results from this and our previous report (Liu et al.,
1995) support the hypothesis that increased intracellular
[Ca2] is required for lateral immobilization of CD2. First,
depletion of intracellular Ca2 prevents the decrease in CD2
fractional mobility in cells stimulated by cross-linking of
the TCR/CD3 complex (the present study) and prevents a
significant portion of the CD2 immobilization induced by
pairs of anti-CD2 mAbs (Liu et al., 1995). The difference
between the fractional mobility of CD2 with and without
EGTA  ionomycin pretreatment is 20–25% in cells stim-
ulated either by cross-linking of the TCR/CD3 complex or
by pairs of anti-CD2 mAbs. Second, kinetic studies show
that [Ca2]i increases 10 min before CD2 becomes immo-
bilized, either by cross-linking of the TCR/CD3 complex
(the present study) or by pairs of anti-CD2 mAbs (Liu et al.,
1995). Third, for each experimental treatment the fraction of
cells with elevated [Ca2]i is equal to the fraction of cells
with decreased CD2 mobility. Fourth, inhibition of the
activity of CaM or CaM kinase, which are dependent on
increased [Ca2]i, completely prevents CD2 immobilization
in cells stimulated by cross-linking of the TCR/CD3 com-
plex. Although these results strongly suggest that increased
[Ca2]i is necessary for CD2 immobilization, it is possible
that Ca2-independent signaling pathways triggered by T
cell stimulation are also involved. The requirement, if any,
for activation of such pathways remains to be elucidated.
CaM, an intracellular Ca2 binding protein, binds to and
regulates the function of enzymes such as kinases and
phosphatases and of cytoskeletal proteins such as actin in T
lymphocytes (Premack and Gardner, 1992). Among other
activities, CaM binds to lymphocyte plasma membranes
upon cell stimulation by PHA and concanavalin A; this
binding is inhibited by TFP or W-7. The concentration of
TFP that inhibits CaM binding to the membrane by 50%
(IC50) is 20–30 M (Lee et al., 1987). Although the dis-
crepancy between this value and the IC50 value found here
for inhibition of Ca2/CaM-mediated CD2 immobilization
remains to be explained, the ability of TFP to prevent CD2
immobilization is unlikely to be due to nonspecific effects
such as those observed at high concentrations of the inhib-
itor (10 M) (Davis et al., 1983; Valverde et al., 1981).
Another CaM inhibitor, W-7, causes inhibition of CaM
binding to the membrane (Lee et al., 1987) and of CD2
immobilization induced by cross-linking of the TCR/CD3
complex at similar concentrations.
Ca2/CaM-dependent protein kinase II (CaM kinase)
also plays an important role in T lymphocyte activation
(Bland et al., 1993; Hanson and Schulman, 1992; Nghiem et
al., 1993). CaM kinase is activated by CaM binding to the
regulatory domain of the enzyme, which leads to deinhibi-
tion of kinase activity. Autophosphorylation of a conserved
threonine residue in the regulatory domain slows CaM
dissociation, thereby prolonging kinase activity. Autophos-
phorylation of the regulatory domain also changes the ki-
nase from a Ca2-dependent to a Ca2-independent form,
thus potentiating the response to transient Ca2 signals
(Schulman, 1993; Schulman et al., 1992). Eventually, de-
phosphorylation of CaM kinase renders the enzyme inac-
tive. Here we find that [Ca2]i increases immediately after
cell stimulation, whereas CD2 becomes immobilized 10
min later, and that the fraction of cells with elevated [Ca2]i
declines 30 min after cell stimulation, whereas CD2 remains
immobilized for 60 min. This sequence of events is consis-
tent with the kinetics of CaM kinase activation. Ca2/CaM-
induced autophosphorylation of CaM kinase could maintain
the enzyme in an activated state and thereby prolong the
immobilization of CD2. CaM kinase has broad substrate
specificity; the enzyme phosphorylates caldesmon, inter-
mediate filaments, microtubule-associated proteins, cal-
cineurin, and other substrates (Hanson and Schulman,
1992). CaM kinase could regulate interactions between cy-
FIGURE 8 Concentration dependence of inhibition
of the reversal of CD2 immobilization by cyclosporine
A. Jurkat cells were pretreated with various concentra-
tions of CsA and then stimulated by cross-linking the
TCR/CD3 complex with OKT3 GaM. CD2 fractional
mobility was measured 1.5–3.5 h after the addition of
GaM. Data points represent the mean  SEM of 47–
103 measurements of CD2 fractional mobility (f) from
one or two experiments at each CsA concentration.
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toskeletal proteins and the cytoplasmic domain of CD2 by
phosphorylation of these or other protein targets.
Calcineurin, a Ca2-dependent protein phosphatase, de-
phosphorylates phosphoserine and phosphothreonine resi-
dues on many substrates of the Ca2-dependent kinases.
The enzyme is therefore an important feedback regulator of
Ca2-dependent phosphorylation (Klee, 1991; Premack and
Gardner, 1992). Ca2/CaM activates calcineurin by binding
to the A subunit of the enzyme (Hubbard and Klee, 1989).
Calcineurin activity is also modulated by CaM kinase- or
PKC-mediated phosphorylation of a serine residue within
the CaM-binding domain, which prevents CaM binding
(Hashimoto and Soderling, 1989). In T lymphocytes, both
antigen-dependent (TCR-mediated) and -independent
(CD2-mediated) pathways activate calcineurin, which in
turn dephosphorylates the CD3 -chain and activates the
transcription factor NF-AT. NF-AT then translocates from
the cytoplasm to the nucleus and initiates transcription of
interleukin-2 and other genes (Alexander et al., 1989; Bierer
et al., 1991, 1993; Elliott et al., 1984; Emmel et al., 1989;
Granelli-Piperno et al., 1986; Kino et al., 1987a,b; Kronke
et al., 1984; Premack and Gardner, 1992; Thomson, 1989;
Tocci et al., 1989). CsA inhibits these calcineurin-depen-
dent activities by binding to its intracellular receptor cyclo-
philin, which then forms a complex with calcineurin and
inhibits calcineurin phosphatase activity (Bierer et al., 1993;
Clipstone and Crabtree, 1992; Dutz et al., 1993; Emmel et
al., 1989; Flanagan et al., 1991; Fruman et al., 1992; Liu et
al., 1991, 1992; Schreiber, 1991; Schreiber and Crabtree,
1992). Here we find that CsA specifically prevents the
reversal of CD2 immobilization upon cross-linking of the
TCR/CD3 complex; the concentration dependence of this
effect agrees quantitatively with that for inhibition of cal-
cineurin phosphatase activity in Jurkat cells activated by
OKT3 and PMA (Fruman et al., 1992). It therefore appears
that calcineurin phosphatase activity is involved in the re-
versal of CD2 immobilization induced by T cell stimulation.
Calcineurin could act to reverse CD2 immobilization by
dephosphorylating cytoskeleton-associated substrates such
as MAP-2 and tau (Klee, 1991).
This work suggests that two Ca2/CaM-dependent en-
zymes, CaM kinase and calcineurin phosphatase, are in-
volved in the CD2 immobilization and the subsequent re-
versal of CD2 immobilization, respectively, in T cells
stimulated by cross-linking of the TCR/CD3 complex. The
mechanism by which simultaneous activation of enzymes
with opposing functions could result in sequential CD2
immobilization and reversal of immobilization is likely to
involve differential Ca2/CaM affinities and kinetics of the
two enzymes. CaM binds with 100-1000-fold greater affin-
ity to calcineurin than to CaM kinase (Klee, 1991), and
calcineurin activation is more rapid and requires lower
concentrations of Ca2 than does CaM kinase activation.
Thus calcineurin activation is likely to occur immediately
upon a TCR-mediated increase in [Ca2]i, whereas the
relatively low [Ca2]i is still insufficient to activate CaM
kinase. This delay in CaM kinase activation could explain
the 10-min delay between the increase in [Ca2]i and the
immobilization of CD2. As [Ca2]i increases, sufficient
Ca2/CaM could be generated to activate CaM kinase; the
resulting autophosphorylation of CaM kinase could then
prolong the activity of this enzyme even after the peak of
[Ca2]i is reached. Activated CaM kinase could also phos-
phorylate a serine residue within the CaM-binding domain
of calcineurin, thereby preventing stable CaM binding to
calcineurin and deactivating the phosphatase (Hashimoto
and Soderling, 1989). By these mechanisms CaM kinase
activity could become dominant, such that CD2 immobili-
zation is sustained for 60 min after TCR-mediated cell
stimulation. As [Ca2]i then decreases, CaM kinase could
become deactivated, both because of decreased Ca2/CaM
binding and because of calcineurin-mediated dephosphory-
lation of the autoregulatory residues on CaM kinase that
potentiate enzyme activity. The increased calcineurin activ-
ity and decreased CaM kinase activity could eventually
result in dephosphorylation of CaM kinase substrate phos-
phorylation sites, leading to the reversal of CD2 immobili-
zation. Studies similar to those reported here, on cells with
mutations in CD2 and CD2-associated proteins, could fur-
ther define these molecular mechanisms.
T cell activation regulates the strength of cell-cell adhe-
sion mediated by the receptor-ligand pair CD2-CD58 (Hahn
et al., 1993). Stimulation of cells by anti-CD3 mAb induces
a transient increase in CD2 avidity for CD58, reaching a
maximum at 30 min after cell stimulation and returning to
basal levels within 90 min (Hahn et al., 1993). Here we find
that TCR-mediated increases in [Ca2]i induce CD2 immo-
bilization, and that the CD2 immobilization spontaneously
reverses between 1 and 2 h after cell stimulation. Thus the
kinetics of changes in CD2 mobility upon cell stimulation
appear to correlate temporally with the effects of TCR-
mediated regulation of CD2 avidity for CD58.
The ability of [Ca2]i to modulate CD2 mobility is likely
to contribute to changes in T cell adhesivity to target mem-
branes. T cell stimulation through the TCR/CD3 complex or
through CD2 could induce rapid increases in [Ca2]i, acti-
vating CaM and CaM kinase and leading both to phosphor-
ylation of CD2 or a closely associated protein and to lateral
immobilization of CD2. Because there is a 10-min delay
between the TCR/CD3- or CD2-induced [Ca2]i increase
and CD2 immobilization, CD2 is capable of anisotropic
redistribution from noncontact regions of the T cell mem-
brane into sites of contact with target membranes during this
time period. Confocal fluorescence microscopy has recently
shown that CD2 redistributes into sites of contact with
model bilayers expressing CD58 on a time scale of10 min
(Zhu et al., manuscript in preparation). After the 10-min
delay, immobilization of CD2 could maintain this adhesion
molecule at high density at the contact sites, thereby de-
creasing the chemical activity of the stabilized CD2-CD58
adhesion complexes and increasing cellular adhesion
strength. Subsequently, activation of calcineurin could
cause both dephosphorylation of the previously phosphor-
ylated residues on CD2 or a closely associated protein, and
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reversal of CD2 immobilization. This reversal of CD2 im-
mobilization 1–2 h after cell stimulation could allow CD2 to
redistribute laterally away from contact sites, thus destabi-
lizing CD2-CD58 binding interactions and facilitating T cell
“deadhesion” (detachment) from target membranes. This
model could underlie the observations that an increase in
[Ca2]i both stabilizes interactions between T cells and
APCs, and reduces the ability of T cells to migrate (Don-
nadieu et al., 1994; Negulescu et al., 1996).
The topology of the contact site between apposing T
lymphocyte and APC membranes could enhance cell-cell
adhesion strength by augmenting the mechanisms that reg-
ulate CD2 mobility. It has recently been suggested that
kinases associated with the inner surface of the T cell
plasma membrane are included within such contact sites,
whereas membrane-associated phosphatases are physically
excluded from such sites (Shaw and Dustin, 1997). Prolon-
gation of CaM kinase action, which appears to be involved
in the immobilization of cell surface CD2, and prevention of
calcineurin phosphatase action, which appears to mediate
the reversal of CD2 immobilization, could stabilize immo-
bilization of CD2 at the contact site and thereby promote
adhesive cell-cell interactions. It has also been proposed that
cross-linking of CD58 on APCs induces immobilization of
class II MHC proteins in the membranes of these cells
(Bierer et al., 1989). Because MHC proteins present antigen
to the TCR and thereby stimulate and maintain T cell
activation, this observation raises the intriguing possibility
that the adhesion strength of interactions between T cells
and APCs could be regulated not only by immobilization of
receptors on the T cell membrane, but also by immobiliza-
tion of ligands for T cell surface receptors on the APC
membrane.
More generally, phosphorylation and dephosphorylation
activities may be important in modulating adhesion medi-
ated by a variety of receptor/ligand pairs. For example,
chemoattractant (fMLP) stimulation of neutrophils induces
repeated transient increases in [Ca2]i, and inhibition of
calcineurin retards release of neutrophils from sites of ad-
hesion to vitronectin (Hendey et al., 1992). Transient in-
creases in neutrophil [Ca2]i could regulate cellular adhe-
sion strength by modulating the lateral mobility of
vitronectin receptors, which are -v and -3-like integrins
(Lawson and Maxfield, 1995). In one such model, increased
[Ca2]i could immobilize cell surface integrins, leading to
an increase in cellular adhesion strength, whereas subse-
quent calcineurin activation could reverse receptor immo-
bilization and promote release of cells from adhesive sur-
faces by allowing lateral diffusion of adhesion molecules
away from contact sites.
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